Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy

Tumor-specific IL-9–producing CD8+Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

(2014) Yong Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Utilizing TH9 cells as a novel therapeutic strategy for malignancies

(2013) Yong Lu et al.   OncoImmunology

Th9 cells promote antitumor immune responses in vivo

(2012) Yong Lu et al.   JOURNAL OF CLINICAL INVESTIGATION

Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation

(2012) J. Kline et al.   JOURNAL OF IMMUNOLOGY

Type 17 CD8+ T cells display enhanced antitumor immunity

(2009) C. S. Hinrichs et al.   BLOOD

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

(2009) Luca Gattinoni et al.   NATURE MEDICINE

Tumor-specific Th17-polarized cells eradicate large established melanoma

(2008) P. Muranski et al.   BLOOD

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION